Adaptive Biotechnologies Corporation

It earns money two distinct ways: clinical payors are billed per test after a diagnostic report is delivered, while biopharmaceutical and data customers pay through a mix of upfront fees, per-sample charges, milestones and installments tied to delivering blocks of sequencing data, with the clinical testing side supplying the larger share. It has also committed a fixed slice of its revenue, whatever that amount turns out to be, to an outside financing party until a set multiple of an original payment has been repaid.

It scales the way many companies with a fixed conversion process do, mainly by running more volume through existing laboratory and sequencing capacity rather than through a different cost structure at larger size, and CompanyGraph groups it with several hundred other companies that scale in this same way. In its own recent history revenue has grown while profit has not followed in step: it has posted a net loss in multiple years on file, the amount owed to it by customers has grown faster than revenue, and it names a history of losses and continued investment needs as the first risk in its own disclosures.

Its testing process depends heavily on one named equipment maker, Illumina, for the sequencing systems it runs samples through, their maintenance and repair, the reagents built specifically for them, and the software that manages laboratory data, while other processing chemicals come from a broader set of vendors on ordinary terms and every test also requires a physical sample supplied by a healthcare provider or research customer. It also relies on third-party platforms, including Epic's records system and Flatiron Health's oncology software, to deliver results into physicians' existing ordering workflows.

Ordering physicians depend on it for a usable clinical report, the commercial insurers, government programs and medical institutions who are actually billed depend on it to justify that charge, and separately biopharmaceutical companies and academic institutions depend on it for sequencing results, licensed immune-system data and trial-related testing. Its own disclosures show revenue concentrated among a small number of counterparties, including one undisclosed customer and the named pair Genentech, Inc. and Roche Group, and its separate collaboration agreement with Genentech was later discontinued.

At the level of its basic operating shape, running physical samples through a largely fixed conversion process, CompanyGraph groups it with several hundred other companies that run the same kind of system, so that shape by itself is common rather than distinctive. The company's own account instead points to its accumulated regulatory authorizations, its patent portfolio, and the use of its test as a measurement standard inside other companies' drug trials as what it considers its points of difference, though CompanyGraph has not independently tested whether competitors could copy these.

The industry pattern this company is grouped under expects growth to be capped mainly by how much physical volume a fixed conversion process can run through it, and its own account partly bears that out by naming laboratory capacity and turnaround time as one limit on its growth. But its own account extends the ceiling well beyond physical throughput, also naming market adoption, payor coverage and reimbursement, regulatory approval timelines, the availability of materials and data, and its ability to hire and keep specialized scientific, technical and sales staff as limits it sets on itself.

In its own risk disclosures the company names its history of losses and ongoing need for investment first, followed by whether the market and payors accept and pay for its tests, whether it can manage its own capacity and growth, and the risk of laboratory errors tied to depending on a limited number of, or in some cases a single, supplier. It also names its own physical laboratories, concentrated in two cities, and its reliance on outside biopharmaceutical partners to carry its testing and data work into therapies, as dependencies it flags itself.

It operates under direct oversight from the FDA, from CMS under CLIA, and from CAP accreditation, plus state-level laboratory licensing in the states where it holds certification and separate certification for the version of its test sold outside the United States, and it names a pending change in how a category of laboratory-developed tests is regulated, alongside a related legislative proposal that has not been enacted, as live regulatory pressure. Because payors rather than patients are billed for its core test, coverage and reimbursement decisions by commercial and government payors are a further outside pressure it names on its own account.